Yaohai Bio-Pharma today announced the launch of its end-to-end mRNA CRDMO platform, designed to support global partners across the full development lifecycle.
In recent years, mRNA technology has made strong progress, especially in vaccines and emerging therapies. Looking ahead, it is expected to play a bigger role in cancer treatment, rare diseases, and personalized medicine. However, the development process is still complex and challenging.
From sequence design to plasmid preparation, mRNA synthesis, purification, LNP delivery, and final fill-finish, every step is closely connected. Therefore, many companies are looking for integrated solutions to improve efficiency and reduce risk.
A Fully Integrated mRNA Platform
Yaohai Bio-Pharma has built a one-stop platform that connects all key steps. As a result, clients can move faster from early research to clinical and commercial stages.
The platform includes:
- Plasmid DNA development and GMP manufacturing
- mRNA synthesis and IVT process optimization
- LNP formulation and delivery development
- Analytical testing and quality control
- Drug product formulation and aseptic fill-finish
- Regulatory support for global submissions
Meanwhile, all services are designed to work together seamlessly, helping ensure consistent quality and smooth project transfer.
Core Technology Capabilities
Yaohai’s platform is supported by four key technology modules:
- Plasmid Platform
High yield and stable quality, providing a strong starting point for mRNA production - mRNA Platform
Supports both conventional mRNA and saRNA, with high capping efficiency and integrity - LNP Platform
Efficient encapsulation and stable delivery using advanced microfluidic technology - Analytical & QC Platform
Full testing capabilities, meeting both China and U.S. regulatory requirements
In addition, these platforms are scalable, supporting projects from early-stage research to large-scale production.
Broad Applications
The platform can support a wide range of mRNA-based products, including:
- mRNA vaccines
- Protein replacement therapies
- Antibody-based therapies (such as TCEs)
- In vivo CAR therapies
- Gene editing applications
Key Advantages
Yaohai Bio-Pharma offers several important benefits:
- End-to-End Integration
Covers the full process from plasmid to final drug product - Full Lifecycle Support
From process development to GMP production and regulatory submission - Proven Experience
Scalable processes that improve efficiency and reduce risks such as impurities - Global GMP Standards
Facilities meet China, U.S., and EU requirements - Flexible Service Model
Customized support based on project stage and client needs
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with extensive expertise in microbial expression systems. We focus on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and innovative vaccines. From R&D to commercial manufacturing, we offer full-lifecycle solutions. Our mission is to build an open, integrated CRO/CDMO/MAH platform that supports global partners from discovery to market.
